Table 2.
The clinical characteristics of onset T2DM group before and after treatment
| Onset T2DM (baseline) | Onset T2DM (after treatment) | t | P | |
|---|---|---|---|---|
| n | 109 | 104 | ||
| Wnt5a (ng/ml) | 64.73 ± 8.49 | 67.52 ± 3.06 | 3.228 | 0.001 |
| BMI (kg/m2) | 27.9 ± 9.28 | 25.14 ± 2.41 | 3.008 | 0.003 |
| SBP (mmHg) | 118.8 ± 16.34 | 104.8 ± 16.47 | 6.225 | <0.001 |
| DBP (mmHg) | 72.40 ± 6.87 | 81.05 ± 10.94 | −6.873 | <0.001 |
| TC (mmol/L) | 4.60 ± 1.02 | 4.03 ± 0.75 | 4.661 | <0.001 |
| TG (mmol/L) | 1.64 ± 1.24 | 1.15 ± 0.53 | 3.779 | <0.001 |
| HDL (mmol/L) | 1.14 ± 0.28 | 1.54 ± 0.87 | −4.472 | <0.001 |
| LDL (mmol/L) | 2.78 ± 1.31 | 2.05 ± 0.83 | 4.881 | <0.001 |
| FBG (mmol/L) | 7.28 ± 2.64 | 6.07 ± 1.44 | 4.178 | <0.001 |
| 2hPG (mmol/L) | 11.37 ± 3.68 | 8.21 ± 1.98 | 7.853 | <0.001 |
| HbA1c (%) | 7.84 ± 3.37 | 6.57 ± 2.04 | 3.344 | 0.001 |
Clinical characteristics of onset T2DM group and lifestyle improvement and metformin treatment for 3 months. Data are expressed as mean ± SD or as percentages for normal distribution. Non-normally distributed values are presented as median (IQR)
BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, TC Total cholesterol, TG Triglyceride, HDL High-density lipoprotein, LDL Low-density lipoprotein, FPG Fasting plasma glucose, 2hPG 2-h plasma glucose, HbA1c Haemoglobin A1c